# Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease

> **NCT00225173** · PHASE2 · TERMINATED · sponsor: **Stanford University** · enrollment: 45 (estimated)

## Conditions studied

- Hodgkin Disease

## Interventions

- **DRUG:** Doxorubicin
- **DRUG:** Vinblastine
- **DRUG:** Cyclophosphamide
- **DRUG:** Etoposide
- **DRUG:** Vincristine
- **DRUG:** Bleomycin
- **DRUG:** Gemcitabine
- **DRUG:** Vinorelbine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT00225173
- **Lead sponsor:** Stanford University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2001-10
- **Primary completion:** 2005-09
- **Final completion:** 2006-09
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2014-08-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00225173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00225173, "Combination Chemotherapy +/- Radiation in High Risk Hodgkin's Disease". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT00225173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*